SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Second quarter summary
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com.
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.
Focus on genetic mitochondrial diseases
NeuroVive out-licenses targeted LHON therapy to BridgeBio
Strategic in-licensing broadens the project portfolio
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 […]